Zhuang, Y., Calderon, C., Marciniak, S., Bouman-Thio, E., Szapary, P., Yang, T., . . . Xu, Z. (2016). First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. European Journal of Clinical Pharmacology, 72(11), 1303-1311.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Zhuang, Yanli, et al. "First-in-human Study to Assess Guselkumab (anti-IL-23 MAb) Pharmacokinetics/safety in Healthy Subjects and Patients with Moderate-to-severe Psoriasis."
European Journal of Clinical Pharmacology 72, no. 11 (2016): 1303-1311.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Zhuang, Yanli, et al. "First-in-human Study to Assess Guselkumab (anti-IL-23 MAb) Pharmacokinetics/safety in Healthy Subjects and Patients with Moderate-to-severe Psoriasis."
European Journal of Clinical Pharmacology, vol. 72, no. 11, 2016, pp. 1303-1311.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.